Two Sigma Advisers LP grew its stake in bluebird bio Inc (NASDAQ:BLUE) by 3,004.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 462,500 shares of the biotechnology company’s stock after purchasing an additional 447,600 shares during the period. Two Sigma Advisers LP owned about 0.94% of bluebird bio worth $82,371,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Meeder Asset Management Inc. boosted its position in bluebird bio by 2,110.3% during the 4th quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock worth $114,000 after buying an additional 612 shares during the period. NuWave Investment Management LLC acquired a new stake in bluebird bio during the 4th quarter worth approximately $135,000. Ladenburg Thalmann Financial Services Inc. boosted its position in bluebird bio by 454.2% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after buying an additional 813 shares during the period. Biondo Investment Advisors LLC acquired a new stake in bluebird bio during the 3rd quarter worth approximately $203,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in bluebird bio during the 2nd quarter worth approximately $211,000.
BLUE has been the topic of several recent research reports. Maxim Group lifted their target price on shares of bluebird bio from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, November 30th. Cantor Fitzgerald set a $113.00 target price on shares of bluebird bio and gave the stock an “underweight” rating in a research report on Monday, December 11th. Barclays restated an “overweight” rating and set a $209.00 price target (up previously from $162.00) on shares of bluebird bio in a report on Wednesday, December 13th. Jefferies Group upgraded shares of bluebird bio from a “hold” rating to a “buy” rating and raised their price target for the stock from $130.00 to $211.00 in a report on Monday, December 11th. Finally, Oppenheimer began coverage on shares of bluebird bio in a report on Wednesday, December 20th. They set a “market perform” rating for the company. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $187.60.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.84). The company had revenue of $4.17 million during the quarter, compared to the consensus estimate of $7.11 million. bluebird bio had a negative net margin of 947.42% and a negative return on equity of 28.09%. The business’s revenue was up 169.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.88) EPS. equities analysts expect that bluebird bio Inc will post -8.25 earnings per share for the current year.
In other news, insider Philip D. Gregory sold 2,250 shares of bluebird bio stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $200.00, for a total value of $450,000.00. Following the completion of the sale, the insider now owns 32,522 shares in the company, valued at approximately $6,504,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jason Cole sold 25,000 shares of bluebird bio stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $195.91, for a total transaction of $4,897,750.00. Following the completion of the sale, the insider now owns 44,798 shares of the company’s stock, valued at approximately $8,776,376.18. The disclosure for this sale can be found here. Insiders sold a total of 64,598 shares of company stock valued at $12,370,309 in the last quarter. 3.90% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “bluebird bio Inc (BLUE) Shares Bought by Two Sigma Advisers LP” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/03/14/bluebird-bio-inc-blue-shares-bought-by-two-sigma-advisers-lp.html.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.